Exhaled Nitric Oxide: An Adjunctive Tool in the Diagnosis and Management of Asthma
|
|
- Clarence Bailey
- 5 years ago
- Views:
Transcription
1 Exhaled Nitric Oxide: An Adjunctive Tool in the Diagnosis and Management of Asthma Jason Debley, MD, MPH Assistant Professor, Pediatrics Division of Pulmonary Medicine University of Washington School of Medicine Seattle Children s Hospital
2 Bronchial Reactivity Symptoms / Exacerbations ASTHMA Airway Inflammation Airway Remodeling Measure to assist with Dx and guide treatment? Airflow Obstruction (Limitation: 50% of children with mild-mod asthma have normal spirometry at baseline) Treatment (steroids) Diagnosis and Assessment of Asthma Control
3 Nitric Oxide: ubiquitous signaling molecule with many physiologic effects Regulation of vascular tone (e.g. pulmonary vascular bed) Regulation of platelet aggregation airway smooth muscle relaxation Neurotransmitter (e.g. memory formation) Host Defense: macrophage dependent antimicrobial effects (viral, bacterial, parasitic) Tumoricidal effects
4 Nitric Oxide Synthesis L-arginine 3 isoforms NOS (nitric oxide synthase) NO Neuronal (nnos): constitutive, greatest expression by neuronal cells in CNS Endothelial (enos): constitutive, greatest expression endothelial cells but present in many cells types Inducible (inos): inducible, expressed primarily by airway epithelial cells (eosinophils, mast cells)
5 Fraction of Exhaled Nitric Oxide (FENO): A Noninvasive Marker of Airway Inflammation in Asthma FENO higher in asthmatic than in healthy individuals (first described in early 1990 s) FENO decreases after corticosteroid treatment Baraldi et al. J Pediatr 1997;131:381-5
6 Excess FENO in Asthma Produced Predominantly by inos Expressed by Airway Epithelial Cells
7 What is the Physiologic Role of Nitric Oxide in the Lower Airways? Freely diffusible signaling molecule that appears to play a homeostatic role in several aspects of airway physiology Basal airway tone Airway responsiveness Host defense/innate immunity Pro-inflammatory or Counter-regulatory? A clear understanding of the physiologic roles of airway nitric oxide in health and disease is lacking (animal models contradictory - less data from humans)
8 Airway Nitric Oxide and Host Defense NO is a toxic free radical with antimicrobial properties - believed to be important in host defense. Limited human data suggests rhinovirus infection stimulates increased nasal inos and NO production, and that higher NO levels are associated with reduced symptoms and faster viral clearance Sanders et al. J Allergy Clin Immunol. 2004;113:
9 Pro-inflammatory vs. Counter-regulatory Properties of NO in the Airways Under physiologic conditions, endogenous NO release appears to tonically suppress microvascular permeability of the airway mucosa. At high concentrations, NO appears to: increased vascular permeability cytotoxic effects on respiratory epithelial cells evidence that NOS inhibitors suppress in vitro chemotaxis of human blood eosinophils, monocytes, and neutrophils
10 The biologic properties of nitric oxide in the upper and lower airways are complex Which of its properties predominates in health or disease, and whether NO in the airways should always be regarded as primarily beneficial or harmful, are still unanswered questions
11 FENO as a Biomarker of Inflammation in Asthma
12 FENO in Exhaled Breath is Flow Dependent FENO is expiratory flow rate dependent ( expiratory flow rate > FENO) NO flux (flow independent) Single breath on-line FENO measurements must be at a constant expiratory flow rate (very low) ATS/ERS recommends on-line FENO measurements be performed at an expiratory flow rate of 50 ml/sec Many published studies (especially prior to 2005) did not use a flow rate of 50mL/sec. Be careful when comparing FENO values between studies Flow Dependent
13 FENO: Relationship Between FENO, Asthma, and Atopy atopic asthma > atopic without asthma nonatopic asthma > non-atopic Jouaville et al. Clin Exp Allergy 2003;33: Nordvall et al. Allergy 2005;60:469-75
14 FENO Associated with Airway Reactivity in Asthmatics FENO associated with airway reactivity to inhaled histamine and methacholine Dupont et al. Am J Respir Crit Care Med 1998;157:
15 FENO Associated with Eosinophilic Airway Inflammation in Asthmatics FENO associated with eosinophils in bronchial mucosa (bronchial biopsy) and sputum Payne et al. Am J Respir Crit Care Med 2001;164: Covar et al. J Allergy Clin Immunol 2004;114: Jatakanon et al. Thorax.1998;53(2):91-5
16 Potential Clinical Uses of FENO as a Biomarker in Asthma Adjunctive diagnostic test for asthma Predictor of steroid responsiveness Identification of a distinct asthma phenotype? Predictor of loss of asthma control Longitudinal monitoring to adjust therapy Marker of compliance with steroid therapy
17 240 steroid naïve adults referred for evaluation of respiratory symptoms Equivalent FENO at 50mL/sec 32 ppb
18 FENO as a Diagnostic Test for Asthma Sensitivity Specificity Peak Flow Variability Peak Flow improvement with steroid 0% 24% 93% 93% Spirometry (FEV1 <80%) 29% 93% Improvement in spirometry (>15%) with steroid 12% 100% Sputum eosinophils > 3% 86% 88% FENO > 20 ppb (flow = 50mL/sec) 88% 79% Gold Standard: Airway reactivity to methacholine + >12% improvement in FEV1 with albuterol Smith et al. Am J Respir Crit Care Med 2004;169(4):473-8
19 Equivalent FENO at 50mL/sec 30 ppb
20 FeNO Eos count FEV1
21
22 Nonsmokers Smokers
23 FENO Measurement to Determine Steroid Responsiveness
24 Steroid Responsiveness in Relationship to FENO in Patients with Non-specific Respiratory Symptoms Am J Respir Crit Care Med 2005;172:
25 61% of subjects used ICS prior to study participation Relatively low baseline FENO and sputum eosinphil %
26 FENO as a marker of a distinct asthma phenotype?
27 Can Markers of Airway Inflammation in Exhaled Breath Predict Response of Childhood Asthma to Fluticasone vs. Montelukast? Characterizing the Response to a Leukotriene Receptor Antagonist and an Inhaled Corticosteroid (CLIC) trial J Allergy Clin Immunol 2005;115:
28 Predictors of Response to Fluticasone vs. Montelukast J Allergy Clin Immunol 2005;115:
29 Pediatric Asthma Controller Trial (PACT) Predictors of response to fluticasone vs. montelukast (ACD = asthma control days)
30 Baseline FEV 1 <80% pred Baseline FEV 1 80% pred r=- 0.62, p=0.001
31 FENO measured in 495 adult asthmatics in Severe Asthma Research Program Aim: Determine whether FENO identified a unique asthma phenotype Methods: Cohort classified by FENO 35ppb vs. >35ppb Results: Subjects with FENO >35ppb Younger patients; Younger when diagnosed with asthma More atopic (greater skin test positivity, higher IgE and blood eosinophils) Greater airway reactivity Greater sputum eosinophilia Greater bronchodilator responsiveness Greatest hyperinflation (RV, RV/TLC) Most frequent ED visits for exacerbations (OR 2.5)
32 FENO to predict loss of asthma control
33 FENO and asthma control assessed using ACQ in prospective study of 341 unselected adult asthmatics followed in an asthma and allergy clinic (Belgium)
34 24 wk observational study 40 children with stable asthma on inhaled corticosteroids eligible for ICS reduction Every 8 weeks ICS dose cut by 50% if clinically indicated Sputum eosinophils, ENO, and bronchial hyperreactivity at each visit to predict success/failure of ICS dose reduction Odds of Exacerbation during ICS Reduction Zacharaslewicz et al. Am J Respir Crit Care Med 2005;171:
35
36 eno as a Marker of Patient Compliance with Prescribed Inhaled Steroid in Childhood Asthma r 2 =0.56, p=0.001 r 2 =0.59, p= Eur Respir J 2002;19: Pediatr Crit Care Med 2004;5:48-52
37 Can We Use FENO as a Tool to Monitor Asthma Longitudinally?
38 Asthma Management Based on Measures of Airway Inflammation vs. Symptom/Lung Function-Based Strategy 74 adults moderate-severe asthma RCT of 2 management strategies to titrate inhaled corticosteroids (ICS) British Thoracic Society asthma management guidelines vs. Minimum ICS dose to maintain sputum eosinophils <3% (induced sputum) No difference in average daily dose of ICS between groups Green et al. Lancet 2002;360:
39 Which FENO cut-off to use in a RCT?? (expiratory flow = 50mL/sec) FENO cut-off of between ppb seems to discriminate between healthy individuals and atopic asthmatics FENO of > 35 ppb reasonable predictor of > 3% eosinophils in sputum FENO > ppb seems to be best cut-off to: Predict steroid responsiveness Predict a loss of asthma control Should cut-off be customized for individual patients?? (e.g. 30 or 50% increase from baseline)
40 Summary of RCTs Comparing FENO to Guideline Based Management Approach No trial to data has assessed a FENO based approach in a cohort of purely atopic asthmatics No trial has looked at change from best baseline FENO
41 FENO Measurement: How is it Done? Single breath maneuver at a constant expiratory flow rate from a deep inspiration Standardized procedures established/published (ATS) Approved by FDA in 2004 for clinical use CPT code. Reimbursement still somewhat problematic Most patients age 6 years and older can perform Patient with Asthma
42 Strength of Evidence Supporting Utility of FENO in the Diagnosis and Management of Asthma Marker of airway eosinophilic/allergic airway inflammation Adjunctive diagnostic test for atopic asthma A- Predictor of steroid responsiveness B+ Identification of a distinct asthma phenotype B+ Predictor of loss of asthma control C+ A- Assist in assessing compliance with steroid therapy B Longitudinal monitoring to adjust therapy * D+ * Contradictory results from published RCTs may reflect differences in algorithms and FENO cut-offs used
43 Unanswered Questions RCT using change from a subject s best baseline FENO to guide therapy? RCT in atopic asthmatics Peripheral/ alveolar FENO measurements?better correlation with asthma control
44
45 Development of Wheezing Phenotypes in Early Childhood Prevalence of Wheezing in Early Childhood eno to identify?
46 Active Study: FeNO in Wheezy Infants & Toddlers Ongoing study (2005- ) Longitudinal Study of FeNO,Symptoms, Exacerbations, and Lung Function in Infants & Toddlers with Recurrent Wheezing Aims: Can FeNO predict: 1. persistence of wheezing? 2. wheezing frequency or severity? 3. change in lung function? 4. assist in the diagnosis of asthma in infants and toddlers? Study Design: - Prospective observational study - 47 infants (9-24 months of age) with history of at least 3 episodes of wheezing - Study visits every 6 months from enrollment through age 3 yrs, then annually through age 6 years. PI: Debley - NIH/NHLBI K23 HL077626
47 Noninvasive Measures in Wheezy Infants and Toddlers Predictors FeNO -single breath during ipft -tidal breathing awake and asleep Outcome measures Lung function (infant lung function testing) Albuterol responsiveness during lung function testing Asthma symptoms during follow-up Exacerbations of wheezing during follow-up
48 SB-eNO (ppb) Enrollment FeNO Levels Acceptable FeNO plateau achieved in 86% of SB-eNO exhalation manuevers 3 acceptable FeNO plateau values achieved in 44 subjects SB-eNO Reproducibility: Mean Intrasubject Coefficient of Variation (CV%) = 6.2% (range %) Intraclass Correlation Coefficient = Enrollment SB-eNO Levels Mean SB-eNO level = 27.8 ppb (s.d. 16.7) Range 3 76 ppb
49 Association Between Enrollment FeNO and Change in Lung Function Over 6 Months in Wheezy Infants/Toddlers Multivariable Linear Regression FEV 0.5 ß Coefficient ( FEV 0.5 z-scores) P value Enrollment SB-eNO (10ppb increments) Gender Age at enrollment (1 month increments) FH Asthma (yes/no) Eczema (yes/no) Sustained ICS use during follow-up (yes/no) Tobacco Smoke Exposure (yes/no)
50 SB-eNO and Bronchodilator Responsiveness in Wheezy Infants/Toddlers Pre- and post-bronchodilator ipfts completed in 37 of 44 subjects Bronchodilator response: > 12% improvement in FEV 0.5 or > 25% improvement in FEF 25-75
51 Enrollment SB-eNO and Subsequent Exacerbations of Wheezing Treated with Oral Steroids by Primary Care/ED Physicians Over First 6 Months of Follow-up
52 FeNO as a Predictor of Persistence of Wheezing at Age 3 Years ROC curve for enrollment FeNO as a predictor of persistence of wheezing at age 3 years (defined as treatment of wheezing with bronchodilators or corticosteroids over at least the last 6 months of follow-up prior to age 3 years). Sensitivity of 77%, specificity of 92%, positive predictive value (PPV) of 94%, and negative predictive value (NPV) of 71%
The FDA Critical Path Initiative
The FDA Critical Path Initiative Clinical Considerations for Demonstration of Dose-response for Inhaled Corticosteroids - Exhaled Nitric Oxide Model Badrul A. Chowdhury, MD, PhD Director Division of Pulmonary
More informationExhaled Biomarkers Asthma & COPD. AS Paul DM Seminar 30 March 07
Exhaled Biomarkers Asthma & COPD AS Paul DM Seminar 30 March 07 Introduction Diagnosis and course of COPD/Asthma Clinical information Pulmonary function tests Arterial blood gases Chest X-raysX No direct
More informationUsing Patient Characteristics to Individualize and Improve Asthma Care
Using Patient Characteristics to Individualize and Improve Asthma Care Leonard B. Bacharier, M.D. Associate Professor of Pediatrics Clinical Director, Division of Allergy, Immunology, & Pulmonary Medicine
More informationNG80. Asthma: diagnosis, monitoring and chronic asthma management (NG80)
Asthma: diagnosis, monitoring and chronic asthma management (NG80) NG80 NICE has checked the use of its content in this product and the sponsor has had no influence on the content of this booklet. NICE
More informationLife-long asthma and its relationship to COPD. Stephen T Holgate School of Medicine University of Southampton
Life-long asthma and its relationship to COPD Stephen T Holgate School of Medicine University of Southampton Definitions COPD is a preventable and treatable disease with some significant extrapulmonary
More information10801 Sixth St, Rancho Cucamonga, CA Tel (909) Fax (909) Visit our web site at:
for the Diagnosis and Management of Asthma and Other Pulmonary Disorders IEHP Policy: Based on a review of the currently available literature, there is insufficient evidence to support the use of FE NO
More informationAsthma COPD Overlap (ACO)
Asthma COPD Overlap (ACO) Dr Thomas Brown Consultant Respiratory Physician Thomas.Brown@porthosp.nhs.uk Dr Hitasha Rupani Consultant Respiratory Physician Hitasha.rupani@porthosp.nhs.uk What is Asthma
More informationAllergy and Immunology Review Corner: Chapter 75 of Middleton s Allergy Principles and Practice, 7 th Edition, edited by N. Franklin Adkinson, et al.
Allergy and Immunology Review Corner: Chapter 75 of Middleton s Allergy Principles and Practice, 7 th Edition, edited by N. Franklin Adkinson, et al. Chapter 75: Approach to Infants and Children with Asthma
More informationSearching for Targets to Control Asthma
Searching for Targets to Control Asthma Timothy Craig Distinguished Educator Professor Medicine and Pediatrics Penn State University Hershey, PA, USA Inflammation and Remodeling in Asthma The most important
More informationCorporate Medical Policy
Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: exhaled_nitric_oxide_measurement 2/2009 3/2018 3/2019 3/2018 Description of Procedure or Service Asthma is
More informationThis is a cross-sectional analysis of the National Health and Nutrition Examination
SUPPLEMENTAL METHODS Study Design and Setting This is a cross-sectional analysis of the National Health and Nutrition Examination Survey (NHANES) data 2007-2008, 2009-2010, and 2011-2012. The NHANES is
More information7/7/2015. Somboon Chansakulporn, MD. History of variable respiratory symptoms. 1. Documented excessive variability in PFT ( 1 test)
Definition of Asthma GINA 2010: Chronic inflammatory disorder of the airways Airway hyper-responsiveness Recurrent wheezing, breathlessness, chest tightness, coughing Variable, reversible airflow obstruction
More informationOptimal Assessment of Asthma Control in Clinical Practice: Is there a role for biomarkers?
Disclosures: Optimal Assessment of Asthma Control in Clinical Practice: Is there a role for biomarkers? Stanley Fineman, MD Past-President, American College of Allergy, Asthma & Immunology Adjunct Associate
More informationCOPD and Asthma: Similarities and differences Prof. Peter Barnes
and Asthma: Similarities and Differences and Asthma: 1 Imperial College Peter Barnes FRS, FMedSci, National Heart & Lung Institute Imperial College, London, UK p.j.barnes@imperial.ac.uk Royal Brompton
More informationImportance of fractional exhaled nitric oxide in diagnosis of bronchiectasis accompanied with bronchial asthma
Original Article Importance of fractional exhaled nitric oxide in diagnosis of bronchiectasis accompanied with bronchial asthma Feng-Jia Chen, Huai Liao, Xin-Yan Huang, Can-Mao Xie Department of Respiratory
More informationClinical Implications of Asthma Phenotypes. Michael Schatz, MD, MS Department of Allergy
Clinical Implications of Asthma Phenotypes Michael Schatz, MD, MS Department of Allergy Definition of Phenotype The observable properties of an organism that are produced by the interaction of the genotype
More informationMEDICAL POLICY. Proprietary Information of YourCare Health Plan
MEDICAL POLICY PAGE: 1 OF: 6 If the member's subscriber contract excludes coverage for a specific service it is not covered under that contract. In such cases, medical policy criteria are not applied.
More informationAsthma and obesity, implications for airway inflammation and Bronchial Hyperresponsiveness
Asthma and obesity, implications for airway inflammation and Bronchial Hyperresponsiveness Fernando Holguin MD MPH Asthma Institute University of Pittsburgh Obesity Trends* Among U.S. Adults BRFSS, 1990,
More informationExhaled Nitric Oxide Today s Asthma Biomarker. Richard F. Lavi, MD FAAAAI FAAP
Exhaled Nitric Oxide Today s Asthma Biomarker Richard F. Lavi, MD FAAAAI FAAP Objectives Describe exhaled nitric oxide physiology and pathophysiology Review the current literature regarding exhaled nitric
More informationClinical Benefits of FeNO Monitoring in Asthma RYAN BURTON, MS, RPFT
Clinical Benefits of FeNO Monitoring in Asthma RYAN BURTON, MS, RPFT Disclosures I am an employee of Circassia Pharmaceuticals. Objectives Nitric Oxide Inflammation in Asthma Phenotyping Personalized Medicine
More informationOutline FEF Reduced FEF25-75 in asthma. What does it mean and what are the clinical implications?
Reduced FEF25-75 in asthma. What does it mean and what are the clinical implications? Fernando Holguin MD MPH Director, Asthma Clinical & Research Program Center for lungs and Breathing University of Colorado
More informationDR REBECCA THOMAS CONSULTANT RESPIRATORY PHYSICIAN YORK DISTRICT HOSPITAL
DR REBECCA THOMAS CONSULTANT RESPIRATORY PHYSICIAN YORK DISTRICT HOSPITAL Definition Guidelines contact complicated definitions Central to this is Presence of symptoms Variable airflow obstruction Diagnosis
More informationAsthma Phenotypes, Heterogeneity and Severity: The Basis of Asthma Management
Asthma Phenotypes, Heterogeneity and Severity: The Basis of Asthma Management Eugene R. Bleecker, MD Professor and Director, Center for Genomics & Personalized Medicine Research Professor, Translational
More informationCurrent Asthma Therapy: Little Need to Phenotype. Phenotypes of Severe Asthma. Cellular Phenotypes 12/7/2012
Subbasement Membrane Thickness(µm) 12/7/212 Current Asthma Therapy: Little Need to Phenotype Phenotypes of Severe Asthma Most mild and to some degree moderate asthmatics respond well to currently available
More informationExhaled Nitric Oxide and Exhaled Breath Condensate in the Management of Respiratory Disorders
Medical Coverage Policy Effective Date... 2/15/2018 Next Review Date... 2/15/2019 Coverage Policy Number... 0439 Exhaled Nitric Oxide and Exhaled Breath Condensate in the Management of Respiratory Disorders
More informationASTHMA TREATMENT EFFICACY ASSESSMENT BY FeNO MEASUREMENT
Bulletin of the Transilvania University of Braşov Series VI: Medical Sciences Vol. 5 (54) No. 2-2012 ASTHMA TREATMENT EFFICACY ASSESSMENT BY FeNO MEASUREMENT Dana ALEXANDRESCU 1 Abstract: The author of
More informationCynthia S. Kelly, M.D. Professor of Pediatrics Eastern Virginia Medical School Division Director Allergy Children s Hospital of The King s Daughters
Cynthia S. Kelly, M.D. Professor of Pediatrics Eastern Virginia Medical School Division Director Allergy Children s Hospital of The King s Daughters Disclosures Speakers bureau of Novartis and Genentech
More informationCurrent Asthma Management: Opportunities for a Nutrition-Based Intervention
Current Asthma Management: Opportunities for a Nutrition-Based Intervention Stanley J. Szefler, MD Approximately 22 million Americans, including 6 million children, have asthma. It is one of the most prevalent
More informationThe Link Between Viruses and Asthma
The Link Between Viruses and Asthma CATHERINE KIER, MD Professor of Clinical Pediatrics Division Chief, Pediatric Pulmonary, and Cystic Fibrosis Center Director, Pediatric Sleep Disorders Center SUNY Stony
More informationPhenotypes of asthma; implications for treatment. Medical Grand Rounds Feb 2018 Jim Martin MD DSc
Phenotypes of asthma; implications for treatment Medical Grand Rounds Feb 2018 Jim Martin MD DSc No conflicts to declare Objectives To understand the varied clinical forms of asthma To understand the pathobiologic
More informationCOPYRIGHTED MATERIAL. Definition and Pathology CHAPTER 1. John Rees
CHAPTER 1 Definition and Pathology John Rees Sherman Education Centre, Guy s Hospital, London, UK OVERVIEW Asthma is an overall descriptive term but there are a number of more or less distinct phenotypes
More informationMEDICAL POLICY. Proprietary Information of Excellus Health Plan, Inc. A nonprofit independent licensee of the BlueCross BlueShield Association
MEDICAL POLICY SUBJECT: MEASUREMENT OF EXHALED MARKERS OF AIRWAY INFLAMMATION IN PATIENTS WITH ASTHMA POLICY NUMBER: 2.01.41 CATEGORY: Technology Assessment EFFECTIVE DATE: 04/15/04 REVISED DATE: 02/17/05,
More informationIdentifying Biologic Targets to Attenuate or Eliminate Asthma Exacerbations
Identifying Biologic Targets to Attenuate or Eliminate Exacerbations exacerbations are a major cause of disease morbidity and costs. For both children and adults, viral respiratory infections are the major
More informationWhat s new in COPD? Apichart Khanichap MD. Department of Medicine, Faculty of Medicine, Thammasat university
What s new in COPD? Apichart Khanichap MD. Department of Medicine, Faculty of Medicine, Thammasat university Management stable COPD Relieve symptoms Improve exercise tolerance Improve health status Prevent
More informationFeNO-based asthma management results in faster improvement of airway hyperresponsiveness
ORIGINAL ARTICLE ASTHMA FeNO-based asthma management results in faster improvement of airway hyperresponsiveness Katrine Feldballe Bernholm 1, Anne-Sophie Homøe 1, Howraman Meteran 1, Camilla Bjørn Jensen
More informationClinical Policy Title: Exhaled nitric oxide for diagnosis of lung disease
Clinical Policy Title: Exhaled nitric oxide for diagnosis of lung disease Clinical Policy Number: 07.01.04 Effective Date: June 1, 2014 Initial Review Date: February 19, 2014 Most Recent Review Date: November
More informationCOPD, Asthma, Or Something In Between? Sharon R. Rosenberg Assistant Professor of Medicine Northwestern University December 4, 2013
COPD, Asthma, Or Something In Between? Sharon R. Rosenberg Assistant Professor of Medicine Northwestern University December 4, 2013 None Disclosures Definitions Asthma Asthma is a chronic inflammatory
More informationBiologic Therapy in the Management of Asthma. Nabeel Farooqui, MD
Biologic Therapy in the Management of Asthma Nabeel Farooqui, MD None Disclosures Objectives Define severe asthma phenotypes and endotypes Describe the role of biologics in asthma management Review pivotal
More informationDifferential diagnosis
Differential diagnosis The onset of COPD is insidious. Pathological changes may begin years before symptoms appear. The major differential diagnosis is asthma, and in some cases, a clear distinction between
More informationASTHMA-COPD OVERLAP SYNDROME 2018: What s All the Fuss?
ASTHMA-COPD OVERLAP SYNDROME 2018: What s All the Fuss? Randall W. Brown, MD MPH AE-C Association of Asthma Educators Annual Conference July 20, 2018 Phoenix, Arizona FACULTY/DISCLOSURES Randall Brown,
More information(Asthma) Diagnosis, monitoring and chronic asthma management
Dubai Standards of Care 2018 (Asthma) Diagnosis, monitoring and chronic asthma management Preface Asthma is one of the most common problem dealt with in daily practice. In Dubai, the management of chronic
More informationManagement of asthma in preschool children with inhaled corticosteroids and leukotriene receptor antagonists Leonard B. Bacharier
Management of asthma in preschool children with inhaled corticosteroids and leukotriene receptor antagonists Leonard B. Bacharier Department of Pediatrics, Division of Allergy and Pulmonary Medicine, Washington
More informationPulmonary Function Testing: Concepts and Clinical Applications. Potential Conflict Of Interest. Objectives. Rationale: Why Test?
Pulmonary Function Testing: Concepts and Clinical Applications David M Systrom, MD Potential Conflict Of Interest Nothing to disclose pertinent to this presentation BRIGHAM AND WOMEN S HOSPITAL Harvard
More informationIndex. Note: Page numbers of article titles are in boldface type.
Note: Page numbers of article titles are in boldface type. A Action plans, and asthma self-management, 47 51 education on, 48 49 health literacy-based education on, 49 50 Airway hyperresponsiveness, assessment
More informationDo current treatment protocols adequately prevent airway remodeling in children with mild intermittent asthma?
Respiratory Medicine (2006) 100, 458 462 Do current treatment protocols adequately prevent airway remodeling in children with mild intermittent asthma? Haim S. Bibi a,, David Feigenbaum a, Mariana Hessen
More informationDiagnosis and Management of Asthma in Children based on the British Thoracic Society and Scottish Intercollegiate Guidelines Network September 2016
Diagnosis and Management of Asthma in Children based on the British Thoracic Society and Scottish Intercollegiate Guidelines Network September 2016 Diagnosis: There is no lower limit to the age at which
More informationDefining COPD. Georgina Grantham Community Respiratory Team Leader/ Respiratory Nurse Specialist
Defining COPD Georgina Grantham Community Respiratory Team Leader/ Respiratory Nurse Specialist Defining COPD Chronic Obstructive Pulmonary Disease (COPD) is a common, preventable and treatable disease
More informationDo We Need Biologics in Pediatric Asthma Management?
Do We Need Biologics in Pediatric Asthma Management? Ting Fan LEUNG, MBChB, MD, FRCPCH, FAAAAI Professor and Chairman Department of Paediatrics The Chinese University of Hong Kong Asthma and Allergy by
More informationOutcome, classification and management of wheezing in preschool children Paul L.P. Brand
Outcome, classification and management of wheezing in preschool children Paul L.P. Brand Princess Amalia Children s Clinic Isala klinieken, Zwolle the Netherlands p.l.p.brand@isala.nl Valle de la Luna,
More informationMeasurement of Exhaled Nitric Oxide and Exhaled Breath Condensate in the Diagnosis and Management of Respiratory Disorders
Measurement of Exhaled Nitric Oxide and Exhaled Breath Condensate in the Diagnosis and Management of Respiratory Disorders Policy Number: 2.01.61 Last Review: 9/2018 Origination: 2/2007 Next Review: 3/2019
More informationImpact of Asthma in the U.S. per Year. Asthma Epidemiology and Pathophysiology. Risk Factors for Asthma. Childhood Asthma Costs of Asthma
American Association for Respiratory Care Asthma Educator Certification Prep Course Asthma Epidemiology and Pathophysiology Robert C. Cohn, MD, FAARC MetroHealth Medical Center Cleveland, OH Impact of
More informationB Y L E S L I E K U M P F, R R T, C P F T, A E - C
FeNO B Y L E S L I E K U M P F, R R T, C P F T, A E - C LESLIE KUMPF RRT, CPFT, AE-C Graduated from Henry Ford with a degree in Respiratory Therapy in 2006 Currently working on my BSRT Help start the RRT
More informationCOPD or not COPD, that is the question.
COPD or not COPD, that is the question. Asthma-COPD Overlap Syndrome: ACOS Do we really need this? Michelle Harkins Disclosure Slide Slide help - William Busse, MD Organizational Interests ATS, ACCP, ACP
More informationSponsor. Generic drug name. Trial indication(s) Protocol number. Protocol title. Clinical trial phase. Study Start/End Dates.
Sponsor Novartis Generic drug name Fluticasone propionate Trial indication(s) Moderate-severe bronchial asthma Protocol number CQAE397A2202 Protocol title A randomized open label study to assess the utility
More informationA diagnosis of asthma is made on the basis of compatible
383 ASTHMA Exhaled nitric oxide in the diagnosis of asthma: comparison with bronchial provocation tests N Berkman, A Avital, R Breuer, E Bardach, C Springer, S Godfrey... See end of article for authors
More informationSmall Airways Disease. Respiratory Function In Small Airways And Asthma. Pathophysiologic Changes in the Small Airways of Asthma Patients
Small Airways Disease Respiratory Function In Small Airways And Relevant Questions On Small Airway Involvement In How can small airway disease be defined? What is the link between small airway abnormalities
More informationPersonalized medicine in childhood asthma. Dr Mariëlle Pijnenburg, Erasmus MC Sophia, Rotterdam, NL
Thank you for viewing this presentation. We would like to remind you that this material is the property of the author. It is provided to you by the ERS for your personal use only, as submitted by the author.
More informationControversial Issues in the Management of Childhood Asthma: Insights from NIH Asthma Network Studies
Controversial Issues in the Management of Childhood Asthma: Insights from NIH Asthma Network Studies Stanley J. Szefler, MD Helen Wohlberg and Herman Lambert Chair in Pharmacokinetics, Head, Pediatric
More informationKEY WORDS airflow limitation, airway hyperresponsiveness, airway inflammation, airway lability, peak expiratory flow rate
Allergology International. 2013;62:343-349 DOI: 10.2332 allergolint.13-oa-0543 ORIGINAL ARTICLE Stratifying a Risk for an Increased Variation of Airway Caliber among the Clinically Stable Asthma Atsushi
More informationRESPIRATORY CARE IN GENERAL PRACTICE
RESPIRATORY CARE IN GENERAL PRACTICE Definitions of Asthma and COPD Asthma is due to inflammation of the air passages in the lungs and affects the sensitivity of the nerve endings in the airways so they
More informationAsma, BPCO ed Esercizio Fisico Ferrara, 6 e 7 Novembre Overlap asma BPCO. Dr. Marco Contoli
Asma, BPCO ed Esercizio Fisico Ferrara, 6 e 7 Novembre 2015 Overlap asma BPCO Dr. Marco Contoli Sezione di Medicina Interna e Cardio-Respiratoria Dipartimento di Scienze Mediche Università di Ferrara (Sept.
More informationMedical Policy An Independent Licensee of the Blue Cross and Blue Shield Association
Measurement of Exhaled Nitric Oxide and Page 1 of 18 Medical Policy An Independent Licensee of the Blue Cross and Blue Shield Association Title: Measurement of Exhaled Nitric Oxide and Exhaled Breath Condensate
More informationTORCH: Salmeterol and Fluticasone Propionate and Survival in COPD
TORCH: and Propionate and Survival in COPD April 19, 2007 Justin Lee Pharmacy Resident University Health Network Outline Overview of COPD Pathophysiology Pharmacological Treatment Overview of the TORCH
More informationDiagnosing Asthma Comparisons between Exhaled Nitric Oxide Measurements and Conventional Tests
Diagnosing Asthma Comparisons between Exhaled Nitric Oxide Measurements and Conventional Tests Andrew D. Smith, Jan O. Cowan, Sue Filsell, Chris McLachlan, Gabrielle Monti-Sheehan, Pamela Jackson, and
More informationKey words: asthma; dyspnea; exercise-induced bronchoconstriction; nitric oxide
Exhaled Nitric Oxide as a Predictor of Exercise-Induced Bronchoconstriction* Samy M. ElHalawani, DO; Nam T. Ly, MD; Richard T. Mahon, MD; and Dennis E. Amundson, DO Introduction: Exercise-induced bronchoconstriction
More informationInhaled fluticasone decreases bronchial but not alveolar nitric oxide output in asthma
Eur Respir J 21; 18: 635 639 Printed in UK all rights reserved Copyright #ERS Journals Ltd 21 European Respiratory Journal ISSN 93-1936 Inhaled fluticasone decreases bronchial but not alveolar nitric oxide
More informationAsthma in Pediatric Patients. DanThuy Dao, D.O., FAAP. Disclosures. None
Asthma in Pediatric Patients DanThuy Dao, D.O., FAAP Disclosures None Objectives 1. Discuss the evaluation and management of asthma in a pediatric patient 2. Accurately assess asthma severity and level
More informationAirway eosinophils in older teenagers with outgrown preschool wheeze: a pilot study
LETTERS Airway eosinophils in older teenagers with outgrown preschool wheeze: a pilot study To the Editor, Preschool wheezing affects one-third of all children growing up in the UK []. It varies in clinical
More informationMeasurement of Exhaled Nitric Oxide and Exhaled Breath Condensate in the Diagnosis and Management of Asthma and Other Respiratory Disorders
Measurement of Exhaled Nitric Oxide and Exhaled Breath Condensate in the Diagnosis and Management of Asthma and Other Respiratory Disorders Policy Number: 2.01.61 Last Review: 9/2014 Origination: 2/2007
More informationAir Flow Limitation. In most serious respiratory disease, a key feature causing morbidity and functional disruption is air flow imitation.
Asthma Air Flow Limitation In most serious respiratory disease, a key feature causing morbidity and functional disruption is air flow imitation. True whether reversible, asthma and exercise-induced bronchospasm,
More informationHeterogeneity of COPD and Asthma
Heterogeneity of COPD and Asthma from Heterogeneity to Stratification Dr. Y-M Oh Asan Medical Center Seoul Congratulations & Welcome Lee,SD Ohno, Y Park, JS Seo, JB 8 th Internat nal Workshop on Pul. Functional
More informationI have no perceived conflicts of interest or commercial relationships to disclose.
ASTHMA BASICS Michelle Dickens RN FNP-C AE-C Nurse Practitioner/Certified Asthma Educator Ferrell Duncan Allergy/Asthma/Immunology Coordinator, CoxHealth Asthma Center DISCLOSURES I have no perceived conflicts
More informationRecurrent Wheezing in Preschool Children. William Sheehan, MD Associate Professor of Pediatrics Division of Allergy and Immunology
Recurrent Wheezing in Preschool Children William Sheehan, MD Associate Professor of Pediatrics Division of Allergy and Immunology Disclosure I have nothing to disclose related to this talk. Background
More informationAsthma: diagnosis and monitoring
Asthma: diagnosis and monitoring NICE guideline: short version Draft for second consultation, July 01 This guideline covers assessing, diagnosing and monitoring suspected or confirmed asthma in adults,
More informationMethacholine versus Mannitol Challenge in the Evaluation of Asthma Clinical applications of methacholine and mannitol challenges
Methacholine versus Mannitol Challenge in the Evaluation of Asthma Clinical applications of methacholine and mannitol challenges AAAAI San Antonio Tx February 2013 Catherine Lemière MD, MSc Hôpital du
More informationUnderstanding Early Wheezing in the Development of Airflow Limitation in Children
Understanding Early Wheezing in the Development of Airflow Limitation in Children Bradley Chipps, MD Capital Allergy & Respiratory Disease Center Sacramento, CA Western Society of Allergy, Asthma and Immunology
More informationCOPD. Breathing Made Easier
COPD Breathing Made Easier Catherine E. Cooke, PharmD, BCPS, PAHM Independent Consultant, PosiHleath Clinical Associate Professor, University of Maryland School of Pharmacy This program has been brought
More informationEffects of inhaled versus systemic corticosteroids on exhaled nitric oxide in severe acute asthma
Respiratory Medicine (2009) 103, 614e620 available at www.sciencedirect.com journal homepage: www.elsevier.com/locate/rmed Effects of inhaled versus systemic corticosteroids on exhaled nitric oxide in
More informationCOPD: From Phenotypes to Endotypes. MeiLan K Han, M.D., M.S. Associate Professor of Medicine University of Michigan, Ann Arbor, MI
COPD: From Phenotypes to Endotypes MeiLan K Han, M.D., M.S. Associate Professor of Medicine University of Michigan, Ann Arbor, MI Presenter Disclosures MeiLan K. Han Consulting Research support Novartis
More informationBronchial Provocation Results: What Does It Mean?
Bronchial Provocation Results: What Does It Mean? Greg King 1 Department of Respiratory Medicine, Royal North Shore Hospital, St Leonards 2065 2 Woolcock Institute of Medical Research and Sydney Medical
More informationClinical efficacy of montelukast in anti-inflammatory treatment of asthma and allergic rhinitis
Clinical efficacy of montelukast in anti-inflammatory treatment of asthma and allergic rhinitis Kim Hyun Hee, MD, PhD. Dept. of Pediatrics The Catholic University of Korea College of Medicine Achieving
More informationCOPD and Asthma Update. April 29 th, 2017 Rachel M Taliercio, DO Staff, Respiratory Institute
COPD and Asthma Update April 29 th, 2017 Rachel M Taliercio, DO Staff, Respiratory Institute What we ll be talking about COPD: diagnosis, management of stable COPD, COPD exacerbations Asthma: diagnosis,
More informationIncreased Leukotriene E 4 in the Exhaled Breath Condensate of Children With Mild Asthma*
CHEST Original Research Increased Leukotriene E 4 in the Exhaled Breath Condensate of Children With Mild Asthma* Atsushi Shibata, MD; Toshio Katsunuma, MD, PhD; Morimitsu Tomikawa, MD; Aiko Tan, MD; Keisuke
More informationAmanda Hess, MMS, PA-C President-Elect, AAPA-AAI Arizona Asthma and Allergy Institute Scottsdale, AZ
Amanda Hess, MMS, PA-C President-Elect, AAPA-AAI Arizona Asthma and Allergy Institute Scottsdale, AZ Financial Disclosures Advanced Practiced Advisory Board for Circassia Learning Objectives 1. Briefly
More informationExpired nitric oxide levels in adult asthmatics
Allergology International (1996) 45: 85-89 Original Article Expired nitric oxide levels in adult asthmatics Chiharu Okada, Akihiko Tamaoki, Yasushi Tanimoto, Ryo Soda and Kiyoshi Takahashi National Sanatorium
More informationChallenges in Meeting International Requirements for Clinical Bioequivalence of Inhaled Drug Products
Challenges in Meeting International Requirements for Clinical Bioequivalence of Inhaled Drug Products Tushar Shah, M.D. Sr. VP, Global Respiratory Research and Development TEVA Pharmaceuticals 1 Presentation
More informationMeeting the Challenges of Asthma
Presenter Disclosure Information 11:05 11:45am Meeting the Challenge of Asthma SPEAKER Christopher Fanta, MD The following relationships exist related to this presentation: Christopher Fanta, MD: No financial
More informationAsthma in Children with Sickle Cell Disease
December 18, 2018 Asthma in Children with Sickle Cell Disease Robyn Cohen, MD, MPH Director, Division of Pediatric Pulmonology and Allergy Associate Professor of Pediatrics Boston University/Boston Medical
More informationOn completion of this chapter you should be able to: discuss the stepwise approach to the pharmacological management of asthma in children
7 Asthma Asthma is a common disease in children and its incidence has been increasing in recent years. Between 10-15% of children have been diagnosed with asthma. It is therefore a condition that pharmacists
More informationcompare patients preferences and costs for asthma treatment regimens targeting three
APPENDIX I ADDITIONAL METHODS Trial design The Accurate trial lasted from September 2009 until January 2012 and was designed to compare patients preferences and costs for asthma treatment regimens targeting
More informationAsthma Update A/Prof. John Abisheganaden. Senior Consultant, Dept Of Respiratory & Crit Care Medicine Tan Tock Seng Hospital
Asthma Update - 2013 A/Prof. John Abisheganaden Senior Consultant, Dept Of Respiratory & Crit Care Medicine Tan Tock Seng Hospital Asthma A complex syndrome Multifaceted disease Heterogeneous Genetic and
More informationAsthma: Classification, Management, Prevention and New Treatments
Asthma: Classification, Management, Prevention and New Treatments Cori Daines, MD, Professor Pediatric Pulmonary Medicine University of Arizona April 28, 2018 I have no relevant financial relationships
More informationAsthma Management for the Athlete
Asthma Management for the Athlete Khanh Lai, MD Assistant Professor Division of Pediatric Pulmonary and Sleep Medicine University of Utah School of Medicine 2 nd Annual Sports Medicine Symposium: The Pediatric
More informationAsthma Pathophysiology and Treatment. John R. Holcomb, M.D.
Asthma Pathophysiology and Treatment John R. Holcomb, M.D. Objectives Definition of Asthma Epidemiology and risk factors of Asthma Pathophysiology of Asthma Diagnostics test of Asthma Management of Asthma
More informationDiagnosis, Treatment and Management of Asthma
Diagnosis, Treatment and Management of Asthma Asthma is a complex disorder characterized by variable and recurring symptoms, airflow obstruction, bronchial hyperresponsiveness, and an underlying inflammation.
More informationAn update on childhood sleep-disordered breathing
An update on childhood sleep-disordered breathing แพทย หญ งวนพร อน นตเสร ภาคว ชาก มารเวชศาสตร คณะแพทยศาสตร มหาว ทยาล ยสงขลานคร นทร Sleep-disordered breathing Primary snoring Upper airway resistance syndrome
More informationImmunology of Asthma. Kenneth J. Goodrum,Ph. Ph.D. Ohio University College of Osteopathic Medicine
Immunology of Asthma Kenneth J. Goodrum,Ph Ph.D. Ohio University College of Osteopathic Medicine Outline! Consensus characteristics! Allergens:role in asthma! Immune/inflammatory basis! Genetic basis!
More informationAsthma and COPD in older people lumping or splitting? Christine Jenkins Concord Hospital Woolcock Institute of Medical Research
Asthma and COPD in older people lumping or splitting? Christine Jenkins Concord Hospital Woolcock Institute of Medical Research Concord Hospital Woolcock Institute of Medical Research Joe has asthma What
More informationAirway Inflammation in Asthma Chih-Yung Chiu 1,2, Kin-Sun Wong 2 1 Department of Pediatrics, Chang Gung Memorial Hospital, Keelung, Taiwan.
REVIEW ARTICLE Chih-Yung Chiu 1,2, Kin-Sun Wong 2 1 Department of Pediatrics, Chang Gung Memorial Hospital, Keelung, Taiwan. 2 Division of Pediatric Pulmonology, Department of Pediatrics, Chang Gung Memorial
More informationClinical Policy: Fractional Exhaled Nitric Oxide Reference Number: CP.MP.103
Clinical Policy: Reference Number: CP.MP.103 Effective Date: 01/16 Last Review Date: 01/17 Coding Implications Revision Log See Important Reminder at the end of this policy for important regulatory and
More information